All Stories

  1. Prognostic Value of Exercise Testing in Patients with Liver Cirrhosis
  2. Pulmonary Artery and Vein Morphology as an Imaging Biomarker for the Diagnosis of Pulmonary Hypertension
  3. Non-invasive mPAP/VO2 slope as predictor of pulmonary exercise hemodynamics and outcome
  4. How It Really Happened‐the Development of Inhaled Iloprost for Pulmonary Arterial Hypertension
  5. Late Onset Pulmonary Arterial Hypertension Associated With Features of Pulmonary Veno‐Occlusive Disease and Rare Heterozygous Variants of KDR and EIF2AK4
  6. Risikostratifizierung und Behandlungsziele bei pulmonalarterieller Hypertonie
  7. IDO‐1 Promotes Pulmonary Vascular Remodeling Via Kynurenine Pathway in Pulmonary Arterial Hypertension
  8. Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis
  9. Detection of structural pulmonary changes with real-time high-fidelity analysis of expiratory CO2
  10. Soluble Transferrin Receptor-1 in Pulmonary Hypertension Associated with COPD
  11. Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta‐Registry
  12. Significance of Pulmonary Vascular Dysfunction in Chronic Obstructive Pulmonary Disease
  13. Lipid Ratios for Diagnosis and Prognosis of Pulmonary Hypertension
  14. Pulmonary Vascular Disease and Pulmonary Exercise Hemodynamics in Patients With Sjögren's Syndrome – A Cross-Sectional Study
  15. Pathogenic SMAD6 variants in patients with idiopathic and complex congenital heart disease associated pulmonary arterial hypertension
  16. Prognostic Relevance of Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Arterial Pressure Ratio and Its Association With Exercise Hemodynamics in Patients With Normal or Mildly Elevated Resting Pulmonary Arterial Pressure
  17. Association of Phosphodiesterase-5 Inhibitor Treatment With Improved Survival in Pulmonary Hypertension Associated With COPD in the Pulmonary Vascular Research Institute GoDeep Meta-Registry
  18. Prognostic relevance of Exercise Pulmonary Hypertension: Results of the multi-center PEX-NET Clinical Research Collaboration
  19. Reply to: The limits of normal of pulmonary arterial wedge pressure
  20. Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH‐CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative—group 3 pulmonary hypertension
  21. Association of PH-Targeted Therapy and Survival in Precapillary PH with mPAP between 21 and 24 mmHg
  22. Clinical Response to Pulmonary Arterial Hypertension Treatment Does Not Depend on Pulmonary Arterial Wedge Pressure: A Meta-Analysis Using Individual Participant Data from Randomized Clinical Trials
  23. Lung Fibrosis Is Linked to Increased Endothelial Cell Activation and Dysfunctional Vascular Barrier Integrity
  24. Severe pulmonary hypertension in chronic obstructive pulmonary disease – From clinical perspective to histological evidence
  25. Risk stratification and treatment goals in pulmonary arterial hypertension
  26. Pulmonary arterial wedge pressure in healthy subjects: a meta-analysis
  27. The prognostic relevance of exercise pulmonary hypertension in cardiac and pulmonary diseases
  28. Expiratory Venous Volume and Arterial Tortuosity are Associated with Disease Severity and Mortality Risk in Patients with COPD: Results from COSYCONET
  29. Compartment-specific remodeling patterns in end-stage chronic obstructive pulmonary disease with and without severe pulmonary hypertension
  30. The TREK‐1 potassium channel is a potential pharmacological target for vasorelaxation in pulmonary hypertension
  31. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era
  32. CT-derived lung vessel morphology correlates with prognostic markers in precapillary pulmonary hypertension
  33. Long-term sildenafil therapy for pulmonary veno-occlusive disease in association with melphalan therapy for multiple myeloma: A case report
  34. Myocardial strain parameters in pulmonary hypertension are determined by changes in volumetric function rather than by hemodynamic alterations
  35. Pulmonal veno-okklusive Erkrankung (PVOD)
  36. Pulmonale Hypertonie
  37. Let’s Talk About Respiratory Swings!
  38. Physical Activity, Depression and Quality of Life in COPD – Results from the CLARA II Study
  39. Pentastatin, a matrikine of the collagen IVα5, is a novel endogenous mediator of pulmonary endothelial dysfunction
  40. Die neue Definition und Klassifikation der pulmonalen Hypertonie
  41. Basement membrane product, endostatin, as a link between inflammation, coagulation and vascular permeability in COVID-19 and non-COVID-19 acute respiratory distress syndrome
  42. Hypoxia-inducible factor-2 may define different scenarios of COPD development/progression
  43. Apelin-17 to diagnose idiopathic pulmonary arterial hypertension: A biomarker study
  44. Abnormal pulmonary hemodynamics during exercise is associated with exercise capacity in COPD
  45. Prognostic Value of Exercise as Compared to Resting Pulmonary Hemodynamics in Patients with Normal or Mildly Elevated Pulmonary Arterial Pressure
  46. Updated definition of exercise pulmonary hypertension
  47. Single-cell transcriptomics reveals skewed cellular communication and phenotypic shift in pulmonary artery remodeling
  48. Impairment of the NKT–STAT1–CXCL9 Axis Contributes to Vessel Fibrosis in Pulmonary Hypertension Caused by Lung Fibrosis
  49. Pulmonary vascular disease and exercise hemodynamics in chronic liver disease
  50. Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis
  51. Left atrial acceleration factor as a magnetic resonance 4D flow measure of mean pulmonary artery wedge pressure in pulmonary hypertension
  52. Circulating microRNAs as molecular biomarkers for lung adenocarcinoma
  53. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension
  54. Severe Pulmonary Hypertension in COPD
  55. Lung vascular changes as biomarkers of severity in systemic sclerosis–associated interstitial lung disease
  56. Automated vortical blood flow-based estimation of mean pulmonary arterial pressure from 4D flow MRI
  57. Potassium Channels in the Transition from Fetal to the Neonatal Pulmonary Circulation
  58. Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022)
  59. Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of systemic sclerosis-associated interstitial lung disease
  60. Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review
  61. Impairment of Inspiratory Muscle Function after COVID-19
  62. Revisiting the Large-Conductance Calcium-Activated Potassium (BKCa) Channels in the Pulmonary Circulation
  63. PCK2 opposes mitochondrial respiration and maintains the redox balance in starved lung cancer cells
  64. Monocytes and Macrophages Serve as Potent Prostaglandin D2 Sources during Acute, Non-Allergic Pulmonary Inflammation
  65. Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer
  66. The definition of pulmonary hypertension: history, practical implications and current controversies
  67. RGS5 Determines Neutrophil Migration in the Acute Inflammatory Phase of Bleomycin-Induced Lung Injury
  68. Low oxygen levels decrease adaptive immune responses and ameliorate experimental asthma in mice
  69. Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances
  70. Elevated pulmonary vascular resistance predicts mortality in COPD patients
  71. Dysbalance of ACE2 levels – a possible cause for severe COVID‐19 outcome in COPD
  72. Between inflammation and thrombosis: endothelial cells in COVID-19
  73. Chronisch-obstruktive Lungenerkrankung 2021 – die richtige Therapie für den richtigen Patienten
  74. Impact of Smoking Behavior on Survival Following Allogeneic Hematopoietic Stem Cell Transplantation – Smoking Cessation Matters
  75. Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways
  76. The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease
  77. Exercise Pulmonary Resistances Predict Long-Term Survival in Systemic Sclerosis
  78. Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension
  79. Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case series
  80. Phospholipid dynamics in ex vivo lung cancer and normal lung explants
  81. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial
  82. Covid‑19 – was wir sicher wissen
  83. Clinical-Pathological Conference Series from the Medical University of Graz
  84. MR 4D flow-based mean pulmonary arterial pressure tracking in pulmonary hypertension
  85. TMEM16A Potentiation: Possible Drawbacks
  86. Distribution and prognostic significance of gluconeogenesis and glycolysis in lung cancer
  87. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study
  88. Masterplan 2025 der Österreichischen Gesellschaft für Pneumologie (ÖGP) – die erwartete Entwicklung und Versorgung respiratorischer Erkrankungen in Österreich
  89. Endothelial Dysfunction Following Enhanced TMEM16A Activity in Human Pulmonary Arteries
  90. C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study
  91. CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis
  92. Basement Membrane Remodeling Controls Endothelial Function in Idiopathic Pulmonary Arterial Hypertension
  93. Quality of Life and Limitations in Daily Life of Stable COPD Outpatients in a Real-World Setting in Austria – Results from the CLARA Project
  94. Multi-channel lung sound classification with convolutional recurrent neural networks
  95. Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9 May 2020)
  96. No indication of insulin resistance in idiopathic pulmonary arterial hypertension with preserved physical activity
  97. Pulmonary hypertension in chronic obstructive pulmonary disease
  98. Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension
  99. Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue
  100. MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2
  101. Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations
  102. Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis
  103. Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease
  104. Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis?
  105. Debating the new haemodynamic definition of pulmonary hypertension: much ado about nothing?
  106. Gluconeogenesis in cancer cells – Repurposing of a starvation-induced metabolic pathway?
  107. Take your drug and climb Machu Picchu!
  108. IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis
  109. Pulmonary and cardiac drugs: clinically relevant interactions
  110. Hämodynamische Definition der pulmonalen Hypertonie: Kommentar zu der vorgeschlagenen Änderung durch das 6th World Symposium on Pulmonary Hypertension
  111. Advanced interstitial lung fibrosis with emphysema and pulmonary hypertension with no evidence for interstitial lung disease on high resolution CT
  112. Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI)
  113. Disconnect between Fibrotic Response and Right Ventricular Dysfunction
  114. Potential role of exercise echocardiography and right heart catheterization in the detection of early pulmonary vascular disease in patients with systemic sclerosis
  115. Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic PAH
  116. The pulmonary haemodynamics during exercise – research network (PEX-NET) ERS Clinical Research Collaboration: investigating the prognostic relevance of exercise haemodynamics
  117. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis
  118. Quantitative CT‐derived vessel metrics in idiopathic pulmonary fibrosis: A structure–function study
  119. Long non‐coding RNAs influence the transcriptome in pulmonary arterial hypertension: the role of PAXIP1‐AS1
  120. Pulmonary hypertension in chronic lung disease and hypoxia
  121. Whole-Body Lung Function Test–Derived Outcome Predictors in Allogenic Stem Cell Transplantation
  122. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension
  123. Imatinib for right heart failure in COPD
  124. Cologne consensus conference on pulmonary hypertension – Update 2018
  125. Should patients with pulmonary hypertension fly and climb?
  126. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?
  127. Are anticoagulants still indicated in pulmonary arterial hypertension?
  128. Clinical-Pathological Conference Series from the Medical University of Graz
  129. Pulmonary hypertension in hypersensitivity pneumonitis.
  130. Right ventricular tissue doppler echocardiography in pulmonary hypertension
  131. Advancing into the details of pulmonary haemodynamics during exercise
  132. Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis
  133. Right ventricular fibrosis and dysfunction: Actual concepts and common misconceptions
  134. Crackle and Breathing Phase Detection in Lung Sounds with Deep Bidirectional Gated Recurrent Neural Networks
  135. Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach
  136. The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells
  137. Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension
  138. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension
  139. Healthy Lung Vessel Morphology Derived From Thoracic Computed Tomography
  140. Resident cell lineages are preserved in pulmonary vascular remodeling
  141. Pulmonary capillary recruitment in exercise and pulmonary hypertension
  142. Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality
  143. Network Analysis to Risk Stratify Patients With Exercise IntoleranceNovelty and Significance
  144. The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension
  145. No erythropoietin-induced growth is observed in non-small cell lung cancer cells
  146. MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas
  147. An official European Respiratory Society statement: pulmonary haemodynamics during exercise
  148. Importance of kynurenine in pulmonary hypertension
  149. Understanding exercise hemodynamics
  150. TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1α
  151. Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study
  152. Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on p22phox
  153. The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension
  154. Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to Hypoxia
  155. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis
  156. Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension
  157. Automated integer programming based separation of arteries and veins from thoracic CT images
  158. ESC-Leitlinie 2015: Diagnostik und Therapie der pulmonalen Hypertonie
  159. Pulmonale Hypertonie: Kölner Konsensus-Konferenz 2016
  160. Pulmonale Hypertonie bei Lungenkrankheiten: Empfehlungen der Kölner Konsensus-Konferenz 2016
  161. Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different?
  162. Why We Should Care about the Mysteries of Pulmonary Hypertension
  163. Does exercise pulmonary hypertension exist?
  164. Docosahexaenoic acid causes rapid pulmonary arterial relaxationviaKCa channel-mediated hyperpolarisation in pulmonary hypertension
  165. Counter-clockwise vortical blood flow in the main pulmonary artery in a patient with patent ductus arteriosus with pulmonary arterial hypertension: a cardiac magnetic resonance imaging case report
  166. Amitriptyline and carbamazepine utilize voltage-gated ion channel suppression to impair excitability of sensory dorsal horn neurons in thin tissue slice: An in vitro study
  167. Functional and molecular factors associated with TAPSE in hypoxic pulmonary hypertension
  168. TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers
  169. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial
  170. Forschung in Österreich – das Ludwig Boltzmann Institut für Lungengefäßforschung
  171. Survival in patients with borderline pulmonary arterial pressure
  172. Prognostic relevance of differential blood count in pulmonary arterial hypertension
  173. Native myocardial T1 mapping in pulmonary hypertension: correlations with cardiac function and hemodynamics
  174. Circulating endothelial progenitor cells are associated with PAH but they are heterogeneous
  175. Pulmonary arterial pressure in patients with myelodysplastic syndromes
  176. Pulmonal (arterielle) Hypertonie
  177. Pulmonalembolie und direkte orale Antikoagulantien
  178. Letter by Olschewski et al Regarding Article, “Upregulation of K 2P 3.1 K + Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation”
  179. Proposed new definition of exercise pulmonary hypertension decreases false-positive cases
  180. Pulmonale Hypertonie
  181. Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertension – Insights From the IBUKI and AIR Studies –
  182. Selexipag for the Treatment of Pulmonary Arterial Hypertension
  183. Clinical Manifestations of Respiratory Bronchiolitis as an Incidental Finding in Surgical Lung Biopsies: A Retrospective Analysis of a Large Austrian Registry
  184. ESC-Leitlinien 2015 zur pulmonalen Hypertonie
  185. Sleep Related Breathing Disorders and Inflammation — The Missing Link? A Cohort Study Evaluating the Interaction of Inflammation and Sleep Related Breathing Disorders and Effects of Treatment
  186. Cardiopulmonary comorbidities are associated with hemodynamics in pulmonary arterial hypertension
  187. The influence of erythropoietin on growth and survival in non-small cell lung cancer cell lines
  188. Pressure Overload Creates Right Ventricular Diastolic Dysfunction in a Mouse Model: Assessment by Echocardiography
  189. Borderline pulmonary pressures in scleroderma - a ‘pre-pulmonary arterial hypertension’ condition?
  190. Compartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients
  191. Impact of cardiopulmonary comorbidities on pulmonary hemodynamics
  192. Blood Flow Vortices along the Main Pulmonary Artery Measured with MR Imaging for Diagnosis of Pulmonary Hypertension
  193. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization
  194. Imatinib for Pulmonary Arterial Hypertension - Wonder Drug or Killer Drug?
  195. Allgemeine Therapie der pulmonal arteriellen Hypertonie
  196. Einsatz von Imatinib bei Patienten mit Pulmonal Arterieller Hypertonie
  197. Moderne bildgebende Verfahren im Management der pulmonalen Hypertonie
  198. Gezielte Therapie der pulmonal arteriellen Hypertonie (PAH)
  199. Ion channels and transporters as therapeutic targets in the pulmonary circulation
  200. Characterization of Patients With Borderline Pulmonary Arterial Pressure
  201. Reply: Reading of Pulmonary Artery Pressure Tracings: The Best Compromise of Accuracy and Clinical Pertinence
  202. Diagnostik der pulmonalen Hypertonie – Neues nach dem 5. Weltkongress
  203. Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics
  204. Gluconeogenesis in cancer: Door wide open
  205. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients
  206. Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries
  207. Distinct Differences in Gene Expression Patterns in Pulmonary Arteries of Patients with Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis with Pulmonary Hypertension
  208. READING PULMONARY VASCULAR PRESSURE TRACINGS How to handle the problems of zero leveling and respiratory swings
  209. Complete resolution of idiopathic pulmonary arterial hypertension following chemotherapy
  210. Kurzatmiger Patient — nicht immer ist er nur untrainiert
  211. PCK2 activation mediates an adaptive response to glucose depletion in lung cancer
  212. Meprinβ, a novel mediator of vascular remodelling underlying pulmonary hypertension
  213. Quantification of Tortuosity and Fractal Dimension of the Lung Vessels in Pulmonary Hypertension Patients
  214. Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model – role of tumor stroma cells
  215. Changes in Right Ventricular Function Measured by Cardiac Magnetic Resonance Imaging in Patients Receiving Pulmonary Arterial Hypertension–Targeted Therapy
  216. Evaluation of Elevated Mean Pulmonary Arterial Pressure Based on Magnetic Resonance 4D Velocity Mapping: Comparison of Visualization Techniques
  217. Was ist pulmonale Hypertonie?
  218. Non-invasive determination of pulmonary hypertension with dynamic contrast-enhanced computed tomography: a pilot study
  219. Updated Clinical Classification of Pulmonary Hypertension
  220. Pulmonary arterial hypertension
  221. Assessment and Prognostic Relevance of Right Ventricular Contractile Reserve in Patients With Severe Pulmonary Hypertension
  222. Docosahexaenoic acid (DHA)-induced heme oxygenase-1 attenuates cytotoxic effects of DHA in vascular smooth muscle cells
  223. PL-7 Positive Antisynthetase Syndrome and Pulmonary Hypertension
  224. Determination of cardiac output with dynamic contrast-enhanced computed tomography
  225. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
  226. Riociguat for the Treatment of Pulmonary Arterial Hypertension
  227. Pulmonary Hypertension
  228. Biomarkers in Pulmonary Hypertension
  229. A 57-Year-Old Woman With Obesity, Respiratory Insufficiency, and Slowed Mental State
  230. Die frühe Diagnose und Therapie der pulmonalen Hypertonie - Aspekte einer Vision
  231. Zero reference level for right heart catheterisation
  232. Double-Stranded RNA Attenuates the Barrier Function of Human Pulmonary Artery Endothelial Cells
  233. Stellungnahme der Österreichischen Röntgengesellschaft und der Österreichischen Gesellschaft für Pneumologie
  234. Loss of ABCG2 leads to right ventricular diastolic dysfunction in pulmonary hypertension
  235. Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension
  236. Prostacyclins
  237. Prostacyclins
  238. Exercise in Pulmonary Hypertension
  239. HbA1c in pulmonary arterial hypertension: A marker of prognostic relevance?
  240. Pulmonale Hypertonie
  241. Angiostatic Factors in the Pulmonary Endarterectomy Material from Chronic Thromboembolic Pulmonary Hypertension Patients Cause Endothelial Dysfunction
  242. Docosahexaenoic acid-induced unfolded protein response, cell cycle arrest, and apoptosis in vascular smooth muscle cells are triggered by Ca2+-dependent induction of oxidative stress
  243. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries
  244. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure
  245. Peroxisome Proliferator–Activated Receptor–β/δ, the Acute Signaling Factor in Prostacyclin-Induced Pulmonary Vasodilation
  246. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension
  247. Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011
  248. Rechtsherzkatheter-Untersuchung bei pulmonaler Hypertonie
  249. Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations
  250. Regulation der Kaliumkanäle in humanen pulmonal-arteriellen glatten Muskelzellen
  251. Pulmonary vascular resistances during exercise in normal subjects: a systematic review
  252. Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells
  253. Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients
  254. Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension
  255. Prostacyclin and Prostaglandins
  256. Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy
  257. Therapie der pulmonal arteriellen Hypertonie (PAH)
  258. Assessment of Pulmonary Arterial Pressure During Exercise in Collagen Vascular Disease
  259. Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension
  260. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension
  261. Intimal Sarcoma of the Pulmonary Valve
  262. Portopulmonary hypertension: short review
  263. The effect of terbutaline on the absorption of pulmonary administered insulin in subjects with asthma
  264. Borderline Pulmonary Arterial Pressure Is Associated with Decreased Exercise Capacity in Scleroderma
  265. Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension
  266. Noninvasive detection of early pulmonary vascular dysfunction in scleroderma
  267. Endothelin-1 Inhibits Background Two-Pore Domain Channel TASK-1 in Primary Human Pulmonary Artery Smooth Muscle Cells
  268. Bildgebende Verfahren in Diagnostik und Verlaufskontrolle der pulmonalen arteriellen Hypertonie
  269. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy
  270. Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension
  271. Diagnosis and Assessment of Pulmonary Arterial Hypertension
  272. Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension
  273. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review
  274. Inhaled iloprost for the treatment of pulmonary hypertension
  275. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension
  276. Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities
  277. A 55-year-old craftsman with dyspnea and clubbing: a case report
  278. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension
  279. Dana Point: Was ist neu in der Diagnostik der Pulmonalen Hypertonie?
  280. Magnetic Resonance–Derived 3-Dimensional Blood Flow Patterns in the Main Pulmonary Artery as a Marker of Pulmonary Hypertension and a Measure of Elevated Mean Pulmonary Arterial Pressure
  281. Oral and IntestinalCandidaColonization in Patients Undergoing Hematopoietic Stem‐Cell Transplantation
  282. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
  283. Prostacyclin therapies for the treatment of pulmonary arterial hypertension
  284. The Emerging Role of Magnetic Resonance Imaging in the Diagnosis and Management of Pulmonary Hypertension
  285. Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function
  286. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension
  287. Pulmonary Histoplasmosis in Three Austrian Travelers After a Journey to Mexico
  288. Highlights der Pulmonalen Hypertonie-Literatur
  289. Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes
  290. Delayed Processing of Blood Samples Influences Time to Positivity of Blood Cultures and Results of Gram Stain-Acridine Orange Leukocyte Cytospin Test
  291. Aspergillus oryzae Peritonitis in CAPD: Case Report and Review of the Literature
  292. Diagnostik und Therapie der chronischen pulmonalen Hypertonie
  293. Effect of Inhaled Iloprost during Off-Medication Time in Patients with Pulmonary Arterial Hypertension
  294. Diagnostik und Therapie der chronischen pulmonalen Hypertonie
  295. Derzeitige Empfehlungen zur Diagnostik und Therapie der pulmonalen Hypertonie
  296. Therapie der pulmonalarteriellen Hypertonie: Prostazyklin-Analoga
  297. Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension
  298. Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension
  299. Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension
  300. Stellenwert der Lyse bei akuter Lungenembolie
  301. Sildenafil treatment for portopulmonary hypertension
  302. Impact of TASK-1 in Human Pulmonary Artery Smooth Muscle Cells
  303. Pulmonale Hypertonie: Die Zukunft hat begonnen
  304. Mutations of the TGF-β type II receptorBMPR2 in pulmonary arterial hypertension
  305. Inhaled Treprostinil for Treatment of Chronic Pulmonary Arterial Hypertension
  306. Diagnosis and treatment of pulmonary hypertonia
  307. Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension
  308. Enhanced Hypoxic Pulmonary Vasoconstriction in Families of Adults or Children With Idiopathic Pulmonary Arterial Hypertension
  309. Serotonin Transporter Gene Polymorphism in a Cohort of German Patients With Idiopathic Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
  310. Ketamine impairs excitability in superficial dorsal horn neurones by blocking sodium and voltage-gated potassium currents
  311. Ambrisentan Therapy for Pulmonary Arterial Hypertension
  312. Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la hipertensión arterial pulmonar
  313. Medikament�se Therapie der pulmonalen Hypertonie
  314. Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension
  315. Novel case of dup(3q) syndrome due to a de novo interstitial duplication 3q24‐q26.31 with minimal overlap to the dup(3q) critical region
  316. Vasodilators in right heart failure - pro
  317. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertensionA randomized prospective study
  318. Sildenafil Increased Exercise Capacity during Hypoxia at Low Altitudes and at Mount Everest Base Camp
  319. Diagnosis and differential assessment of pulmonary arterial hypertension
  320. Prostanoid therapy for pulmonary arterial hypertension
  321. Prostacyclin and its analogues in the treatment of pulmonary hypertension
  322. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV‐related severe pulmonary hypertension
  323. Reversal of Nocturnal Periodic Breathing in Primary Pulmonary Hypertension After Lung Transplantation
  324. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia
  325. Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension
  326. Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure
  327. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension
  328. Primary pulmonary hypertension may be a heterogeneous disease with a second locus on chromosome 2q31
  329. Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension
  330. Increased neutrophil mediator release in patients with pulmonary hypertension – suppression by inhaled iloprost
  331. Pulmonaler Hochdruck
  332. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension
  333. Sildenafil zur Therapie der schweren pulmonalen Hypertonie und des beginnenden Rechtsherzversagens
  334. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
  335. Inhaled Iloprost for Severe Pulmonary Hypertension
  336. Peripheral airway obstruction in primary pulmonary hypertension
  337. Aerosolized Vasodilators in Pulmonary Hypertension
  338. Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension
  339. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: respondersversusnonresponders
  340. Nocturnal periodic breathing in primary pulmonary hypertension
  341. Outcome after Cardiopulmonary Resuscitation in Patients with Pulmonary Arterial Hypertension
  342. Cellular pathophysiology and therapy of pulmonary hypertension
  343. Recommendations for the Choice of Inhalatory Systems for Drug Prescription
  344. Physiologic basis for the treatment of pulmonary hypertension
  345. Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension
  346. Basic Electrical Properties ofIn situEndothelial Cells of Small Pulmonary Arteries during Postnatal Development
  347. Obstructive Sleep Apnoea and Cardiovascular Diseases - Hypothesis of Pathophysiological Interlinks
  348. Does the tuberous sclerosis complex include clivus chordoma? A case report
  349. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension
  350. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy
  351. Diagnostik der akuten Lungenembolie - Empfehlungen der Deutsche Gesellschaft für Pneumologie -
  352. Prävalenz von Schlaganfall und transitorischer ischämischer Attacke (TIA) bei obstruktiver Schlaf-Apnoe: eine retrospektive Erhebung an 187 konsekutiven Patienten1
  353. Abnormal Pulmonary Artery Pressure Response in Asymptomatic Carriers of Primary Pulmonary Hypertension Gene
  354. Enhanced Release of Superoxide from Polymorphonuclear Neutrophils in Obstructive Sleep Apnea
  355. Inhalative Strategien zur Verbesserung der pulmonalen Hämodynamik und des Gasaustausches bei Sepsis und schwerer pulmonaler Hypertonie
  356. Behandlung der Pulmonal Arteriellen Hypertonie
  357. Screen–printed enzyme sensors for l-lysine determination
  358. Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial
  359. Inhaliertes Prostazyklin und Iloprost bei schwerer sekundärer pulmonaler Hypertonie durch Lungenfibrose1
  360. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
  361. Severe Microcirculatory Abnormalities Elicited byE. coliHemolysin in the Rabbit Ileum Mucosa
  362. Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis
  363. Physiologie und Pathophysiologie der pulmonalen Zirkulation
  364. Vasotrope Therapie und Beatmung bei pulmonaler Hypertonie
  365. Effect of bupivacaine on ATP-dependent potassium channels in rat cardiomyocytes
  366. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost
  367. Abnormalities of Gastric Mucosal Oxygenation in Septic Shock
  368. NO und alternative inhalative Therapieansätze bei pulmonaler Hypertonie
  369. Advantage of buffered solutions or automated capnometry in air-filled balloons for use in gastric tonometry
  370. Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension
  371. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome.
  372. ATP-Dependent Potassium Channel in Rat Cardiomyocytes Is Blocked by Lidocaine
  373. Temperature effects on ventilatory rate, heart rate, and preferred pedal rate during cycle ergometry
  374. Cardiac responses to the Valsalva manoeuvre in different body positions
  375. Thermoregulatory, cardiovascular, and muscular factors related to exercise after precooling
  376. Body temperature related factors diminishing the drive to exercise
  377. Pulmonary Hypertension